CAS 1257051-63-0

THPP-1

CAS: 1257051-63-0

THPP-1

Formel: C₂₃H₂₁ClN₆O₃

Reinheit: ≥98%

Molekulargewicht: 464.9

Ref: 54-BUP10837

(2-(6-Chloropyridin-3-yl)-4-(2-methoxyethoxy)-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)(imidazo[1,5-a]pyridin-1-yl)methanone

CAS: 1257051-63-0

Ref: IN-DA01V2QP

THPP-1

CAS: 1257051-63-0

(2-(6-Chloropyridin-3-yl)-4-(2-methoxyethoxy)-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)(imidazo[1,5-a]pyridin-1-yl)methanone

Formel: C₂₃H₂₁ClN₆O₃

Reinheit: 98%

Molekulargewicht: 464.9

Ref: IN-DG01222425

THPP-1

CAS: 1257051-63-0

THPP-1 is a potent and orally bioavailable inhibitor of PDE10A(Ki of 1 nM and 1.3 nM for human and rat PDE10A, respectively).

Formel: C₂₃H₂₁ClN₆O₃

Reinheit: 99.46%

Farbe und Form: Solid

Molekulargewicht: 464.9

Ref: TM-T8506

THPP-1

CAS: 1257051-63-0

THPP-1 is a potential mechanism for Parkinson's disease. It has been shown to have dose-dependent effects on rat striatal dopamine levels and may act as a prodrug of dopamine. THPP-1 also inhibits the activity of cyclic nucleotide phosphodiesterases, which are enzymes that break down cyclic nucleotides, such as adenosine monophosphate (AMP) and cyclic guanosine monophosphate (cGMP). This inhibition leads to an increase in intracellular cAMP and cGMP levels. THPP-1 has been expressed in the striatum of mice and rats, suggesting that it may be effective in treating Parkinson's disease when administered orally.

Formel: C₂₃H₂₁ClN₆O₃

Reinheit: Min. 95%

Molekulargewicht: 464.9 g/mol

Ref: 3D-HAC05163